1. Pink Sheet

What Will USPTO-FDA Collaboration Look Like? Stakeholders To Weigh In On Proposed Initiatives

 
• By Brenda Sandburg

Agencies are holding public ‘listening session’ to get input on method of use patents and ‘skinny labeling,’ REMS patenting, PTAB proceedings and other topics.

FDA and USPTO
USPTO and FDA holding public meeting to get input on areas for collaboration • Source: Nielsen Hobbs; the Pink Sheet|Shutterstock images

The US Patent and Trademark Office and US Food and Drug Administration are working out how they will collaborate to promote greater access to medicines and increase competition. Industry representatives, patients, payors and other stakeholders will get a chance to provide feedback on potential actions the agencies may take to achieve this goal.

The agencies are holding a public “listening session” on 19 January to obtain input on their joint collaboration initiatives. The...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Access

More from Pink Sheet

ACIP Upheaval Leaves Merck & Co. In A Lurch

 
• By Jessica Merrill and Bridget Silverman

Merck’s newly approved Enflonsia for RSV is one of the products expected to be recommended for use by the CDC Advisory Committee on Immunization Practices later this month.

‘Sex Pill For Women’: Sprout CEO’s Addyi Instagram Post Draws US FDA Warning Letter

 
• By Sue Sutter

Cindy Eckert’s social media post with a People.com story failed to include any risk information, made misleading representations about benefits and omitted material information about the indication, said the agency, which flagged similar concerns about an Addyi radio ad five years ago.

US FDA Chief Counsel Position Awaits HHS General Counsel Confirmation

 
• By Sue Sutter

Robert Foster, HHS deputy general counsel and chief counsel for food, research and drugs, is temporarily heading the Office of Chief Counsel, but a permanent appointee is expected after Michael Stuart's confirmation as HHS general counsel.